<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-005065
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050215
<FILING-DATE>20050216
<DATE-OF-FILING-DATE-CHANGE>20050215
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05618763
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k.htm
<TEXT>
<HTML><HEAD>
<TITLE>
Unassociated Document
</TITLE>
<!-- Licensed to: v-->
<!-- Document Created using EDGARIZER HTML -->
<!-- Copyright 2004 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</HEAD>
<BODY><DIV><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman, serif"><STRONG>SECURITIES AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Washington, D.C. 20549</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, serif"><STRONG>FORM 6-K</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">REPORT OF FOREIGN ISSUER</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Pursuant to Rule 13a-16 or 15d-16 of</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">the Securities Exchange Act of 1934</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>For the month of February 2005</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>Commission File Number 000-5112</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">2</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 16pt; FONT-FAMILY: Times New Roman, serif"><STRONG>pSivida Limited</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">(Translation of registrant&#146;s name into English) </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Level 12 BGC Centre</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">28 The Esplanade</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Perth WA 6000</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">(Address of principal executive offices)</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">(Indicate by check mark whether the registrant files or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F). </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Form 20-F </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Yes </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): 82- ___. </FONT></DIV>
<DIV><BR>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>SIGNATURE </STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, pSivida Limited, has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Date: February 15, 2005</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">pSivida Limited</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT size=2></FONT>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 207pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">By:&nbsp; </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><U>/s/ Aaron Finlay&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 100.65pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">Aaron Finlay</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><EM>Chief Financial Officer and Company Secretary</EM></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV><BR>
<TABLE id=PGBRK cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR vAlign=top>
<TD width="100%" colSpan=3><FONT id=TAB2 style="LETTER-SPACING: 9pt">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD></TR>
<TR>
<TD align=left width="33%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=middle width="34%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=right width="33%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR vAlign=top>
<TD width="100%" colSpan=3><FONT size=1>
<HR style="PAGE-BREAK-AFTER: always" color=black noShade SIZE=2>
</FONT></TD></TR></TABLE>
<TABLE id=HDR cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR>
<TD vAlign=bottom width="100%">&nbsp;</TD></TR></TABLE><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG><EM><U>EXHIBIT INDEX</U></EM></STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>&nbsp;</DIV>
<DIV align=left>
<TABLE cellSpacing=0 cellPadding=0 width="100%">

<TR>
<TD vAlign=top align=left width="9%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif"><STRONG>EXHIBIT 99.1:</STRONG></FONT></DIV></TD>
<TD vAlign=top align=left width="62%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, serif">pSivida Limited Press Release, dated February 15, 2005 (Positive Phase IIa Trial Results in Liver Cancer)</FONT></DIV></TD></TR></TABLE></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left></DIV>
<DIV valign="top"></DIV></DIV></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99.htm
<TEXT>
<HTML><HEAD>
<TITLE>
Unassociated Document
</TITLE>
<!-- Licensed to: v-->
<!-- Document Created using EDGARIZER HTML -->
<!-- Copyright 2004 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</HEAD>
<BODY><DIV>
  <p align="center"><img border="0" src="logo.jpg" width="248" height="79"><BR>
  </p>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left>
  <strong>FOR IMMEDIATE
  </strong><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Arial, sans-serif"><STRONG>RELEASE</STRONG></FONT><FONT id=TAB2 style="COLOR: black; LETTER-SPACING: 161.1pt">&nbsp; &nbsp;</FONT>&nbsp;<FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Arial, sans-serif"><STRONG>&nbsp;</STRONG></FONT><FONT id=TAB2 style="COLOR: black; LETTER-SPACING: 0.9pt">&nbsp; &nbsp;</FONT>&nbsp;<FONT id=TAB2 style="COLOR: black; LETTER-SPACING: 27pt">&nbsp; &nbsp;</FONT>&nbsp;<FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG>&nbsp;</STRONG></FONT><FONT id=TAB2 style="COLOR: black; LETTER-SPACING: 27pt">&nbsp; &nbsp;</FONT>&nbsp;<FONT id=TAB2 style="COLOR: black; LETTER-SPACING: 27pt">&nbsp; &nbsp;</FONT>&nbsp;<FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG> 15</STRONG></FONT><FONT style="DISPLAY: inline;
FONT-SIZE: 9pt; FONT-FAMILY: Times New Roman, serif"><SUP><STRONG>th</STRONG></SUP></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, serif"><STRONG> February 2005</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Positive Phase IIa Trial Results</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Arial, sans-serif"><STRONG>in Liver Cancer </STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 13pt; FONT-FAMILY: Arial, sans-serif"><STRONG><EM>BrachySil</EM></STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif"><SUP><STRONG><EM>TM</EM></STRONG></SUP></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 13pt; FONT-FAMILY: Arial, sans-serif"><STRONG><EM> trial confirms safety and tumor regression in further patients</EM></STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">Global nanotechnology company pSivida Limited (</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>NASDAQ:PSDV, ASX:PSD, Xetra:PSI</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">) is pleased to announce that its trial in inoperable primary liver cancer patients continues to show excellent results. Data from the second patient cohort of the current Phase IIa trial has further demonstrated that BrachySil&#153; (32-P BioSilicon&#153;) is safe and effective in tumor regression with increased efficacy.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">Results of the second group of 4 patients, 12 weeks after their BrachySil&#153; treatment, revealed an average tumor regression by volume of 80% as determined by CT scanning. In some smaller tumors 100% regression was observed, a level of performance not seen with other intratumoral approaches. The study also demonstrated that there were no product-related adverse effects. Patients will continue to be monitored for 6 months post treatment.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">These excellent results follow the announcement in October 2004 of the interim results from the first 4 patients, which also showed no product-related adverse effects and reported up to 60% regression of tumors.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">BrachySil&#153; is a micron-sized particle in which the isotope 32-phosphorus is immobilized. pSivida believes that this product is unique in that it demonstrates a very high degree of isotope retention, thus reducing the risk of soluble radioactive material affecting healthy hepatic tissue or entering the circulation and causing systemic toxicity. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">pSivida&#146;s Managing Director, Mr. Gavin Rezos, said, &#147;This further human evaluation of BioSilicon&#153; has met our expectations in terms of safety and the performance of the fine gauge needle injection procedure. We are also very pleased with the significant level of tumor regression achieved given the low dose being administered. Proof of the ability of BrachySil&#153; to retain radioactivity at the injection site is another significant outcome of the trial.&#148;</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">Other treatments for primary liver cancer include a variety of embolisation and radiofrequency ablation techniques. pSivida believes that BrachySil&#153; potentially offers the interventional radiologist a more versatile and safer product for the treatment of such tumors. The procedure is undertaken without surgery under local anesthetic and patients can be discharged the following day.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">pSivida currently plans to pursue a &#146;device-based&#146; regulatory approval route for BrachySil&#153; which could result in a much shorter development and registration timeframe than that commonly associated with a drug-based approval. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">Following the completion of analysis of the final Phase IIa trial results pSivida expects to begin a dose profiling study during 2005. pSivida then intends to commence multi-centre pivotal registration trials during 2005 involving patients in Asia, Europe and the US. The objective of these trials is to obtain data to support registration of BrachySil&#153; as an approved treatment for primary liver cancer. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>
  <FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial">pSivida plans to expand the use of BrachySil<SUP>TM</SUP> as a treatment for a wider range of solid tumor indications. A Phase IIa clinical trial is scheduled to commence for a second cancer indication within the next year.</FONT><font face="Arial" style="font-size: 11pt"><BR>
  </font></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>
  <FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial">The brachytherapy market is currently over US$600 million per annum and is expected to exceed US$1 billion within the next few years (Bio-Tech Systems). BrachySil&#153; has the potential to significantly expand the current market size through its application to other cancers. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV><BR>
<TABLE id=PGBRK cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR vAlign=top>
<TD width="100%" colSpan=3>&nbsp;&nbsp;</TD></TR>
<TR>
<TD align=left width="33%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=middle width="34%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=right width="33%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR vAlign=top>
<TD width="100%" colSpan=3><FONT size=1>
<HR style="PAGE-BREAK-AFTER: always" color=black noShade SIZE=2>
</FONT></TD></TR></TABLE>
<TABLE id=HDR cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR>
<TD vAlign=bottom width="100%">&nbsp;</TD></TR></TABLE><BR>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">The study has established </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>four </STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">key findings:</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif"><EM>&#183;&nbsp;&nbsp;</EM></FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG><EM>SAFETY - No product related adverse events</EM></STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><EM>&nbsp;</EM></FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">Unlike other liver brachytherapy approaches that involve delivery via the hepatic artery and, in some cases, result in radioactivity affecting healthy tissue, BrachySil&#153; is administered directly into tumors restricting radioactivity to the tumor itself.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif"><EM>&#183;&nbsp;&nbsp;</EM></FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG><EM>EFFICACY - Treated tumors demonstrate significant tumor regression</EM></STRONG></FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">Implantation of tumors with BrachySil&#153; has resulted in tumoricidal activity around the implantation site. Although the primary objective of the study was to determine the safety profile of BrachySil&#153;, CT scan analysis of tumors at the time of treatment and 3 months later demonstrates significant tumor regression in targeted lesions with a maximum regression of 100% from the dose used in the trial. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif"><EM>&#183;&nbsp;&nbsp;</EM></FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG><EM>SPECIFICITY- Retention of radioactivity in the tumor</EM></STRONG></FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">A key finding is that the radioactive 32P-BioSilicon</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><SUP>TM</SUP></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> nanostructured microparticles remain in the tumor with no or insignificant detectable radioactive leakage. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif"><EM>&#183;&nbsp;&nbsp;</EM></FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG><EM>EASE OF APPLICATION - Practical and rapid treatment of tumors with ultrasound and CT guidance</EM></STRONG></FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">The procedure has been shown to be straightforward and accurate for the treatment of tumors. From a market perspective this demonstration is in line with the company&#146;s strategy to develop a simple procedure for the interventional radiologist to selectively treat specific tumors. A multi injector is in design phase to treat larger tumors with multiple implantations from a single entry.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>NOTES ON BRACHYSIL AND COMPETITIVE ADVANTAGES IN BRACHYTHERAPY </STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">1.&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">BrachySil&#153; is being manufactured to worldwide regulatory guidelines by supply chain contract partners including HighForce, Micron Group, Atomising Systems and AEA Technology QSA subsidiary Auriga Medical, a leading global producer and supplier of radioisotopes for healthcare. </FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">2.&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">Brachytherapy treatment utilising BioSilicon</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><SUP>TM</SUP></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> includes the following significant potential advantages: </FONT></TD></TR></TABLE>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 27pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Short range</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> - 32-P isotope has a short active range resulting in less damage to healthy tissue.</FONT></TD></TR></TABLE>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 27pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Immobilization</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> - 32-P device is immobilized in the tumor, significantly reducing risk of leakage or systemic side effects. </FONT></TD></TR></TABLE>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 27pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Ease of application</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> - BrachySil&#153; is delivered under local anesthetic and patients can be discharged the next day.</FONT></TD></TR></TABLE>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 27pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Direct delivery</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> - BrachySil&#153; is delivered via fine gauge needle, minimizing side effects and tissue trauma without the need for shielded rooms or robotic injectors allowing treatment in hospitals without the need for investment in specialised facilities.</FONT></TD></TR></TABLE>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 27pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Range of tumors</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> - fine gauge needle delivery allows potential application to many solid tumors, unlike current brachytherapy products. </FONT></TD></TR></TABLE>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 27pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Distribution</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> - 32-P half-life of 14 days allows more convenient distribution to hospitals and application in the patient. </FONT></TD></TR></TABLE>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 27pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Manufacture</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> - BioSilicon&#153; is radiation hard allowing ease of manufacture of BrachySil&#153; from phosphorous-doped silicon used in the electronics industry without the need to build costly manufacturing facilities.</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=center><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Times New Roman, serif"><STRONG>-ENDS</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR>
<TABLE cellSpacing=0 cellPadding=0 width="100%">

<TR>
<TD vAlign=top align=justify width="39%"><STRONG><FONT face=Arial size=2>Released by:</FONT></STRONG></TD>
<TD vAlign=top align=justify width="39%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top align=justify width="39%">&nbsp;</TD>
<TD vAlign=top align=justify width="39%">&nbsp;</TD></TR>
<TR>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif"><STRONG>In Australia:</STRONG></FONT></DIV></TD>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif"><STRONG>In US:</STRONG></FONT></DIV></TD></TR>
<TR>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">Josh Mann</FONT></DIV></TD>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">Beverly Jedynak</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">Investor Relations</FONT></DIV></TD>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">President</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">pSivida Limited</FONT></DIV></TD>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">Martin E. Janis &amp; Company, Inc.</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">Tel: + 61 8 9226 5099</FONT></DIV></TD>
<TD vAlign=top align=justify width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">Tel: 312-943-1100 ext. 12</FONT></DIV></TD></TR>
<TR>
<TD vAlign=top align=left width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">joshuamann@psivida.com</FONT></DIV></TD>
<TD vAlign=top align=left width="39%">
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=left><FONT style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Arial, sans-serif">bjedynak@janispr.com</FONT></DIV></TD></TR></TABLE>
<DIV valign="top"></DIV></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR>
<TABLE id=PGBRK cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR vAlign=top>
<TD width="100%" colSpan=3>&nbsp;</TD></TR>
<TR>
<TD align=left width="33%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=middle width="34%"><FONT size=1>&nbsp;</FONT></TD>
<TD align=right width="33%"><FONT size=1>&nbsp;</FONT></TD></TR>
<TR vAlign=top>
<TD width="100%" colSpan=3><FONT size=1>
<HR style="PAGE-BREAK-AFTER: always" color=black noShade SIZE=2>
</FONT></TD></TR></TABLE>
<TABLE id=HDR cellSpacing=0 cellPadding=0 width="100%" align=center border=0>

<TR>
<TD vAlign=bottom width="100%">&nbsp;</TD></TR></TABLE><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>NOTES TO EDITORS:</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify>
  <table border="0" cellpadding="0" cellspacing="0" style="border-collapse: collapse" bordercolor="#111111" width="100%" id="AutoNumber1">
    <tr>
      <td width="50%">&nbsp;</td>
      <td width="50%">&nbsp;</td>
    </tr>
    <tr>
      <td width="50%"><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Ticker Symbols<br>
      </STRONG>Australian Stock Exchange<br>
      NASDAQ<br>
      Frankfurt Stock Exchange (Xetra)</FONT></td>
      <td width="50%"><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">
      <br>
      :PSD<br>
      :PSDV<br>
      :PSI</FONT></td>
    </tr>
  </table>
  <BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>pSivida Limited</STRONG></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">pSivida is a global nanotechnology company committed to the biomedical sector and the development of products in healthcare. The company&#146;s focus is the development and commercialisation of a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon&#153;. As a new and exciting biocompatible material, BioSilicon&#153; offers multiple potential applications across the high growth healthcare sector, including controlled release drug delivery, targeted cancer therapies (including brachytherapy and localized chemotherapy), tissue engineering and orthopedics. Potential diagnostics applications are being developed through its subsidiary AION Diagnostics Limited. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">pSivida owns the intellectual property rights to BioSilicon&#153; for use in or on humans and animals. The IP portfolio consists of 24 patent families, 26 granted patents and over 80 patent applications. The core patent, which recognises BioSilicon&#153; as a biomaterial was granted in the UK in 2000 and in the US in 2001. </FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">pSivida is listed on NASDAQ (</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>PSDV</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">), the Australian Stock Exchange (</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>PSD</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">) and in Germany on the Frankfurt Stock Exchange on the XETRA system (</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>German</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">&nbsp;</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Symbol:
PSI. Securities Code (WKN) 358705</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">). pSivida&#146;s shares also trade in the United Kingdom on the OFEX International Market Service (IMS) under the ticker symbol </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>PSD</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">The Company&#146;s strategic partner and largest shareholder is the QinetiQ group, the largest science and technology company in Europe. QinetiQ is the former UK government Defence Evaluation Research Agency and was instrumental in discovering BioSilicon&#153;. pSivida enjoys a strong relationship with QinetiQ having access to its cutting edge research and development facilities. For more information on QinetiQ visit </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; COLOR: #0000ff; FONT-FAMILY: Arial, sans-serif"><U>www.qinetiq.com</U></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">.</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"></FONT>&nbsp;</DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">pSivida has a strong management team with a powerful blend of international experience in biotechnology commercialization, the pharmaceutical industry, licensing and capital markets:</FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Mr Gavin Rezos,</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">&nbsp;</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Managing Director -</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> a former Investment Banking Director of the HSBC Group.</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Dr Roger Brimblecombe,</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">&nbsp;</FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Non Executive Chairman </STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">- former Chairman of SmithKline &amp; French Research and Chairman of MVM Ventures.</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Dr Roger Aston, Director Strategy</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> - former CEO PepTech Ltd and Director of Cambridge Antibody Technology Ltd (UK).</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Professor Leigh Canham, Chief Scientific Officer </STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">- a DERA fellow and the world&#146;s foremost authority on porous silicon and the inventor of BioSilicon&#153;. </FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<TABLE id=list cellSpacing=0 cellPadding=0 width="100%">

<TR style="LINE-HEIGHT: 1.25" vAlign=top>
<TD style="WIDTH: 18pt" align=right><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Symbol, serif">&#183;&nbsp;&nbsp;</FONT></TD>
<TD><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"><STRONG>Dr Anna Kluczewska, Managing Director, AION Diagnostics</STRONG></FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif"> - a former Global Product Manager with Baxter Healthcare Inc, based in Munich and Vienna.</FONT></TD></TR></TABLE>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; FONT-FAMILY: Arial, sans-serif">For more information visit </FONT><FONT style="DISPLAY: inline; FONT-SIZE: 11pt; COLOR: #0000ff; FONT-FAMILY: Arial, sans-serif"><U>www.psivida.com</U></FONT></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><BR></DIV>
<DIV style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align=justify><FONT style="DISPLAY: inline; FONT-SIZE: 9pt; FONT-FAMILY: Arial">This document contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors including: our failure to develop applications for BioSilicon<SUP>TM</SUP> due to regulatory, scientific or other issues. Other reasons are contained in cautionary statements in the Registration Statement on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under
Item&nbsp;3.D, "Risk Factors" therein. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf of pSivida.</FONT></DIV>
<DIV valign="top"></DIV></DIV></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!/`/@#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBD)`Z
MG_(H;MN`M%-WCGKP,]#_`)_/%(74=_\`.,_3Z\U/-'NOOT^_8'I_5_R'T4W<
MI&0<C_#]*0R*`22<#&<`D\G&0!R<=P,GVZ9:E%I---/5-.Z:76ZT'9]GVV>_
M85B1@CIGG_.::[L$+*`3C(!!`ZXY()_G7!?$CXJ_#SX1>%=2\;?$SQ;HO@OP
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MF1M)?3-*\7E0N(?*EE81(Y<$#Y+\`_\`!5O]EKX@?%#PI\*+>Y\?^%-;\>7S
MZ9X)UKQ[\/O$'@_POXFU#!6WMM,UG68K>"9[N<Q06ICWQSRSPQ))NEC+=U\&
M_P#@G[\%OAU=Z=XQ\>P7WQU^,(LDBUGXJ_%>1?$NOWMRS1SW']G6=T'TK0M/
M:[5IHM+TVTBM(BS%$4LQKY/_`."@6C>#OC_^TK^Q)^QWX5TBUN?$^E?%_1_V
MB?B+J&B6]E#<_#[X6?#*TU0);7LT*I/IL/C/4]0ALK")0HDGT^&2/;)Y+#OP
M='+:U2=":Q-64:5>I4Q4*L:=&DJ5-U(OV,J<I23<=I5(2ES1II1DUS?"\79_
MXC91E^&S[#3X;RZ%7-N'\OPG"F(P6+S;-LTJ9KFV#P%3"3S6CC,!A,'BY4,5
M4J..%R[,,/@EA:N*GB<70C45/]H87>1-S@*2S8`!&$S\@.23N"X#=!NS@`<5
M+4%OGREW`@GG!;=C<`Q7/L21^''&*GKRFTW=*RZ+7]=3]D5UOOUV>O:ZLM`H
MHHI`%%)N&<9YSCO2;AG'IUXX_P`^_3WJ>:-VN976ZNK[7VWV"S[;[#J*0,#T
M/Z']:,_7TZ'_``_7I333V:?]+;ONOO`6BFAU()YX.#D&G=:%)2U337=.ZV3T
M[Z-?>`444A(`R>@_'^5,!:*9YB^_3/0^N/SI]`?U^GYIKY!1132P'_UJ-Q-I
M*[T2'44W<,A><D9!QQW[_A3J`33O9WL[/R=D[?<T%%%%`PHHHH`*B<`L,CL!
M]02>/KQQUSGMCF6BIE'F25VO>B]+IOE:DE=-.S:5^ZNGHP[^:M\GN?/7Q`\;
M_$+P=?W=XEIX7'AP3*NG&_OQ:WUZT=ND\ULBEB6N6"3&)%0LR["%+8%=A\./
MB1I_Q`TVXGMXC9:G9.L>HZ=(Q9H2X8Q31DX::"7`"N%R'#HZJR,`[XL0%_#4
M#[-29XM7MG4Z-I-EK5ZI:*Z7=]FU"-XDA;Y%ED4!PY2,-MD8U\S?"2>72_C-
M)I\/V^*UU&WU&TGAU&!+*\<-8G6H);FQB)@@<2Q2/$D0"".8%57=A?XTXHX]
MXJ\+_'KA#AR?$.<9WP9QQFF7Y-C,JSNK@\3'`YEQ)6KT\NQF58ZTL=@Z6%QL
M8X9X%TJ>%J896<ZDU!K[?"Y=@<TX>Q.)6%H8?'8"E4J4ZN&C*#E"ARN:K1^"
M;G'>5^92DI:)6?L_BWXH>._";ZG<W'@-9-"L+IX(=6^W2B.:V,OE07$D:6[F
M(2DKD'*J2.6R#7`V_P"TOJM]-#9VGA.WEN;J5+>WABU"Z>2::5Q'%'&JVARS
M.0!VS@\#(K<^,/QB^'=_-XQ^"]CXCT^]^)-IX"'CO4/#=G,MQ>Z;X9M/%?AK
M1!?ZD(2ZV?VG4=7MH+**X,<ETJW$L*,MO(1\P?#=2GCOP:A()3Q'H2$@Y&5O
M8E.#[$8K\@^D-X@>,GA?XO\`"G!.1>*F?2RCB_"9+F:^NY'PE5K99#.>),RR
M>6%PLED,8UZ&&I82-3#SQ"G5ES<M6<^53??POA^'L]RC&9@\!@JU7`8G&X6J
M\/BL1-5*N!H4*E6G5<*S5.<)U5&LHVE&4HVO[R7?>+?V0_AY^TW\1]!^(_[0
M_A#Q?J(\!ZCI^M^$/!&L^,[J\^&\NII:7=I]JNO!D-M;V5W/8!4NE>_>Y83W
M`9)%C,D3>R^(_BW8^&=9A\#>`M)T.U@TD'3Y+BY:#2O#^CI8H`=.M(H4CMTA
MMHQY>R()"DV+>,>8=M?0'B*\.FZ#K.I*!NT_1]1O$R0!YEMITLZ9)/'^K//'
MYXKX&^&MK+.E[<SCQ)/<3ZA;VDUSIVAZ=K-O/@"61[R?4%<Q7$LUV[S>0`&B
MVL[M(&"_KOCGXC<?\"TO#+PMR3C'/,PSG/JN=8_..+<9A\EAG-3),MQ4<14P
M6"P^%PN6Y5@IXVKB7@UBZ%"C6P^&P4$Y8C$2G5GX/"O#'#<\;Q'Q'2R/+\'6
MQ<L&\73PM*<98RO#"0P]&IC<1*<\1BO84<-2ITZ=64J<82M"--15O>O'7QF\
M5_"OX::IXM\4>'H=?\6ZEJ5EH/PW\'^%R;J]\:>)];C$'A_1;<QM(85O;UA)
M=WLNRWTW2XKO4+MXX+61QPO[*?[,EW\*M3\=_&CXH3V7B?\`:/\`C;J$6N_$
MSQ-;!I;#0+5(8VTCX<>#)ILW%MX.\*6YCL[.,&(:A<6SZE,GFS[G^K6\.V-Q
MJUGK]S%'<WNFVAM=*%P@>/2S*DT5W/91!0L-[>6\HMKFY&91;A[>%HXI+E+K
MKZ_KSA_!U,FR/!94\QS',ZU&A".(S+-<1+%9EBVY>T;Q=?EI^UFI\T6[+W80
MBE:$7+X3,,JH9GGM'.L72H<N6SK/)<'3IJ.'R_$U:,L-B<?2CS-/$U,-4J8:
ME*2;H4JN(Y)?OYI-0`*,9&><'KR.GX"G9'K7F7Q?^+/@KX'?#KQ=\5OB)?S:
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M[E6[:71PSQ)P[QE2C7X6S[)\_P`/];I8*KBLIQ]#'8>A7JSIP5.M4P\ZGLYI
M5(R<96?(U.UFK\;XP^-O@_PC>W.G/+<:KJ-K)BYM=-19?L[[F7RYKAF6".0;
M&8Q%_,``!7YA6)H'[0_@S6+E+:]COM$:62.&.6^1#;F6638B23P-(D!;/!D*
MH?7M7RK\+O"EAXZ\;1:5KMY,;1K74+^Y83*MU?7%LULJ1&9UD8LYG,DK`;W1
M`&92&*^M?%3X&0Z9;6&H>!=.U"\:XN3:WVF0R_:6A9T)MKR%BHD6%6B:.?<9
M.948``,!_G!E/CA])SC7A[.?%S@_+.&L1P-D^=RP/^I>'P5/,,]Q6&C4PU.M
M1HSAA9YE6E2AC*-3$5Z56A4:]I5HX>=&DZ1^T8C(N%<OQ-#*,95Q3QV(H1JQ
MQTIRA0ISO):WGR)2E3ER*2:M9.[>OV7'/%+%%-`ZR1S(KHZ,&5D=258$<,#G
M(([<^U>"?$[XV7'P_P#$L>@QZ+%J"/IEMJ!G>[D@8&XGO8?*V+$XQBS)#%AC
M=T`KI/@WH_B;0/"2Z3XG5A/;WMP^GK+=)=3Q:=-'%*EO+(CMM%O<O=)"C$,M
MOY*[0,A<WQ_XF^%6E:]'9^,[&VN=:>QMY5>;3;F[;[$TEPD8$T43J%#B<;2<
MC+9YK^G^.N*^)<X\',CXGRWBK+O`S/LUGD5?&8OCB.'PM+)IUXU/KF1UX9GA
M)15>M-*IAY2PU*I5P\%5E"ES2B?*Y?A,+0SO$X6O@Z^>X:A&MR4\#9RJJ#I.
M-6,HS?NV;B_>:C*Z]/3?#.LOKN@Z+K+1K;G5M*L-1:W1V<1->VT-P8P[<OL$
MNW.`#@'`S72C^I_F0/Y?X5XI\1/C!\/?@C\&M9^,OBF:\L?AOX-\,V.O:E=:
M+H^H:O=6'AYOL4*W<.DZ9!=:A-;V<$\<UPEO;RF"TAFG8+'"37C/[+/[?'[-
M?[8VI>+]'^!7BO5/$6I>!]/T75?$5IJOA;Q'X9EM++Q!<WMKILL:^(--T\W0
M:?3[F.=;<R&W=$68(98]W[QPY0QU?A_*\54Q"S=TLIRV6-SO"TU]2S"M4PN'
M4\PI.E"%.G2QM1_6*4%&$53Q%'E6O*OA<RXCX>P'$-#AW%9SEF"SS-7B*N59
M#B<=AJ6:8JA0]JZDL+@IU%B,1&E&A7=:5*%10]C4NVHR:^TLCU%>4?'CXDGX
M-_!'XO\`Q<731K)^%_PR\<_$)=(\XV_]JGP;X9U/Q"-.$X#&(WO]G?9A)M.P
MR!B,`UX#^U+^WS^S7^QUJO@[1OCIXMU+P]J'CO2]9U7P[;:7X7\0^))+JRT.
MZLK/49;@:#IVH?8@)M0MDMOM8A^UD7'V8R?9I_+[BR^/WP.^+?[+NM?']KA]
M;^`6M_#KQEXGUJZUG0=3M5U'P!HMOK=IXIDO-`O;6'4I+.6PTK4PUL]F)+NS
M=61&CG4GWHX:M#ZO7JX6K/"U:D5&2C**KI32G2I2Y6I3;4H+EO:2?:QY>*XH
MR/$U>(,BR_B?)<-Q)DV68C$X[#/%X6OB\AC/#*>&S+,\O=3VM+"TG6H8F3KP
MA3J490;ERU$?F[_P3S_X*Y:K^W#\=-6^#>H?!S3_```NG_#SQ%X\@UFS\47&
MN/+%H6M^%M'2REMI=,L?+DN#XE64E&E2/[*5$C;AC]OAT'T%?D7^Q-^T9_P3
M4^*WQ?O?"W[(GAOP]HWQ23P3JVMW\^E?#3Q%X/F_X0^VUGP_;ZQ&^KZKI%C9
MRPR:KJ&C/):),\TLH61%/E$K^E/Q1^*W@'X+^!=>^(_Q-\2Z=X2\&>%[![_6
M-;U2X6&VMX(\A50$[YIYY-D-O;0J\T\SK%&C,<5TYK2IK'1CALMQ.`C4HTE'
M"UG.=24K-.HE/WE[1VLDVFT[-GROA9FF-EP/]?XB\0^'O$"OAL9F-3%<69-/
M+\/E,,-3]C56%G4P:IX6,\#"<E5FXTW:24TG%R?I#ML)8D8"9QCDD;CC\N@X
M/]/RK^%/_!7C]EOXQ?&WP[\!?"3>-#XZ\3>+=3\&6$5]X7U"TTPZII;7HNVD
MU"2(0K`OV&?RY0Q\SR\C(89T?@I_P5\_8D^.WCV#X=^&_B->>'=>ORPT2;QQ
MH.J^$]*UN595ACL[#4]9MK2T.H7+./L>G32QWET`WDPOL;'\MW[`#))_P5(^
M#)CDRI^/GC!\=F5XO%FQ@`>=Q&]3T*X8$UZ66Y)*K1S1YCAL30JX7`_6<,Y0
ME32ER5)1YHRA[T6J:UO&UW[R:1^9>)?CHLJSKPJH^'N?\,Y_E7%_&L>&\_KX
M:OA\WC0H3Q624I*C7PN(:PE>-/,IRBZD9K6G+E::O_>FC`_AD9P1T)'(;D9]
M.V0/2I:Q]6U;3=#TR\U75KZVT_3=/MI[J^O[V>*VM;6T@$CRW%Q/,R1Q1HJ9
M9W90!R3@,1^3OCC_`(+;?L&>!_$=_P"&X?'VN^,9-*N6M;S6/!_A76]:\/-(
MA&Y]/UJ"T^PZO`H)'GZ7-=P[E:+>)5*#Q,/@L3C%)X7#UJ_(H\WLJ4IJ-TK<
MS2M'F=[7LW9V70_>.(>-.$^$(X>?%'$F1\/PQC?U5YOF>#R^5?E2YE1AB:E.
M5;V:<>>4$^5./-:ZO^O5%?)?[,O[;G[.?[76EWFH?!#Q]8^([O37*:MX=O(;
MC1?%&E`8"RWWA_5H[35(K:3)\F[-M]EF"EHI7!!/UDN22?H,>A'7V_*L:M*K
M0J.E6ISI5(Z.%2+C)/>S3LT[>72Q[.59MEF>8"AFF39A@\TR[%1Y\/CL!B:.
M*PM:'2=*O0G.G.+NK2C)K5=QU%%%9GH!11368*,G)]A0)NRN^GS_``6IPWQ*
MT^'4?!VJQS0V5PMLD=^(M0BU&:U(L9!<R%XM)9=0D*P1RLBVP=RX`*.NX5\*
M6NIIX;\=:9K-I<6>FV]QB&*ZTZRU=++2Y[JRN]%DG6+7[>.\F-B;J+5)HI%D
MC>/S-K)$H2IOV_/VUY_V>O#WAWX3_!S38?'_`.UI\:[V/PG\%_AO8/;:C=Z?
MJ>K6]Q##X^\5Z2LR72>$/#TJM<S9$"ZG/;20&YLM+MM9U?2O8O\`A4WQ:\9_
M#WP<_P`1_%^@Q_$1_#^DS^/M&T:SN[CP+'XO^QQKK+^%+V^M'UZUTMKGS5ME
MNWG:2#&(8X]L:_R;])GP=XIX@?#/B7P1ESS'BCA?,LHS++\MPN'RR./QF(X?
MS"68X+%RQ6.S;+I+`TJM2="O"%''8B;A!8>A)P=O3X,X[X?Q.=9[P7/$593P
M&#C_`&OBU3Q4<NP,\RII0RZICJ6%KTHYF\.H8MX>%15\/AZT*U10C4BW\S_`
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MF>+BLF]A4E3KX/$3G]2P3E##RE6I5%.C!--_HG`7">1<(\)XSA[(ZN"AE_UC
M'U:-7"SG*FZN)HQJ8K%8VK)RJ5<;B:]1XC&XK$3J5Z]6M*O7J5*LYL_0KXMZ
M[9:+X`\2-<7$<<NHZ3>:381EU+7%YJ-LUA&D:##N(EG,\Q3+)!%)*1L5B/E;
MX3:';7NIZ19WEGHU[>:CJ[WYBO;#Q4FHVUK`1($2[LHO[$C"V]K-<Q_:9$$C
M/$)FQ@#J;GX._%[QC/:7'BWQ%:JL!5XX]0O&U".&7YD:6+3K"UCTW<4*==OF
M+N261>&'T_X-\+WGAK3K:UU'7[SQ%=K&HDNKF*WMK>+;'M$5A:6J)';VR;<*
MKM/*1UE`^6OZF_U1XV\=O%_)>,^)^`\[X$X.X4RVE@<II<1X3)L7B,R4\?\`
M7\QGB</_`&O2QN"QF*GR87!RH9=F>$H48/$8JK=_5:GC2Q6`R#)JN$PV94<=
MCL96E.K]3G6@J+C25.E:K&FX3A%^]*//!\S?*];KKXD.WE3G/&X!<<#J!QD=
M.,@\\GO8I,<YR1[=O_K?Y]:6O[JA#DNDK+1)*R5DY/9)6;<FW^2U/@VV[?\`
M!_7T_IW/SZ_X*H(I_P""?7[5#$<M\-I4)W,/D;6-(1AP?ERKL"PPV#UX&/YD
M/^"-G[''P=_;"^)GQ?L_CCI^N>(O"WPZT#PCKEKX2L=<U30=(U?6-8U37["*
M\UR71YK2^D&EV]G=1VD<%U;-C4+@,YCE=6_IQ_X*H_\`*/C]JC_LG$G_`*>M
M&K\1/^#<K'_"ROVJ@3C=X.^&X'K_`,C!XO/ISC&3T^M?;9/B*N&X9SNO1JU*
M56GB,)R5*<Y0G!3JT(RY)Q:<;IN]FKG\7^+>3Y3GWTHO!K*<ZRW!9MEF+X8S
MN6*R[,,/3Q>"Q7L:'$=>G'$X:K&=*M!5J-"I*%2,HR]E%23BM/SO_P""L?[,
M7@+]CS]K"R\'_!.QOO"OA#7?ASX3^(_AS2WU;5-4N_#.H76K^(O#THL=3U&X
MN=4DC34/"<NJ64TEW/<6L]P1'<^7%"$_M#_9W\8_\+R_9B^"_C[6[;]]\5O@
MQX"\4:W!D@FY\5^$--U#4H5="5!\Z^F1)-Q7:$(.P*5_E3_X.$7C_P"&VO`"
MJ5=K?]F3P."@?YD9OB1\7BC,@#,,#:PR,,A9@V(V!_I?_85UG3_#_P"P;^R3
MJ>KW=O8Z=:_LV?!9[F[N':*&'?X"\/QH267)\UV54&`Q)`VY(W<7&=7`5^#L
M#B<_GA_J#PF.68XK,:L%AIY?6PLWC_KE2M^Z]@Z,(K$3KU(QE3=K349<N?T?
M,+3R+Z0/CIP]D&%HY9D^&Q."J8/*LOP\:&&P]6AF:AA*6#PE!*-*G16,K0IQ
MHTXTX*<.5122?FGC;X=>*OAGJL-];O='38;AI]-U_3TF18%BE=HH;R91&UI=
MA`B21R,T%VC,O[Y!Y9]5\!_M$3PO%IWCF)[K$D:IK6GI&C1(610;^S,@8HB$
M/)-:[N!EK<+P?H31/'/@GX@7&I^']+O(M7$$*->VUU9SK;7$$DDJ.$CO8XQ<
MHAA(8QQLD0DMV8G>`?F7X[?"_1O!]KIGB#PQ"ME:W5ZUA=Z:KR20P32Q3W,$
MUE'-(3%'(872>%6V1962)=I9*_R<XEX`XE\$,+F_C)]'#C_"YSX<8?%5<7GW
M#4LP6/RZC[+$QP&*7L^>>"SC#X.6(]DZB=#-L%1ES4JM>$&W_I%A<QHY\Z.2
M<29<Z.9SA&.%Q4H*G._+[2*=U[2FY<C=K\DI)MZ^Z?:5C=65_;6U_83Q7-K=
MVZSVT\+AXI8I$61)$9<*=P*G(Z9VYP0!\,?M*G'Q'M"`,CPUI1Z#JM]K@&>.
M0!Q@Y![@U[%^S3K%U?\`A75].GE:>+2-45;)FW?N;:\MDE>V0G)\M;J.XE6-
MG;REN5B4[8U+>.?M+?\`)1[3_L6=,_\`2[7*^T^DAQS2\2?HF<-<<4<+]0CQ
M#GG#>)KX)3E4CAL90K9S@\QH1J-1=6E3S#"XE4JCC%U*:A.48S<DN+AK`SRW
MBZM@)RYWAZ&)A?\`FA*.'J4[]+\DXW6J3NEL?0][X)TSXE?L]7?P\UJ&*XTO
MQY\(I_"-_!.H>*6T\2^$'TF=)5*N"IBO7;`!/0`'(4_R)_\`!&?QOKG[.O\`
MP40D^"GC..:SOO'&G_$3X(^(K(>8([3QIX,EG\0V\LQG6&=4&H>"-6TFU$X0
MM/K,:&'S9(T7^R/X?[F\`^"B"?\`D4_#P&.HQI%H,Y_#N.^.>_\`&5^WC?7O
M['?_``5YU3XM6EN\>E6/Q1^%7QZM8[9)(YM3T'Q$/#UWX[6)'CGW_P!K:O:^
M-M)D6+?M#3O$5=!&G^A?@_?$\#97DR@N7$\&</UZ,;I)XBAE&$I1BHV:;3JQ
MG>-I?NU:]DU_"OTI80X:XG\*/%6,I0EPGXD0RG-)QM&3R3.J]6IBJE?$<T'&
MG"E@,1AXJK/V3ECYQFU[7DJL_P""TGQ+O_CI_P`%!;SX7:!$\Q^&>C>!_@OX
M?MI"?(O/%WB22W\3WD\!C,LA\W4_&=CHD@4"02Z0\:1>8'+_`-.OQB^%&C?!
M+_@F3\7/@_HW[W2_AS^QI\1/!L$SEBUY_8?PCUJQN+V4,<F2_N(YKR;(`,DS
M':``!_+]^Q]X;L?VV_\`@K]>^,M1F_M?PB/CA\2?C_)<!':&;PMX&UV^USX?
M#,9A8V:ZM_P@]B'F90T)6.6*4,R2?UM_MM`I^QE^U>,[B/V;_C9AN02P^&_B
M0<+SW&<=.U?79[66%7#N60O">&I8:=2*O%*K6G!N36EY*3G+FT:Y]7J[?)^!
MF$?$B^D!XIXN,:\.*LXX@RC*YU/9U92RC+,-B:\:=.3YFL/4H8K`T)QYO95?
MJ<$DXTHM?RM?\&_BK_PW-XHX&3^S?\0B3WS'X]^&&SGJ,8!(!PQ`+9(S7WI_
MP<9^,=0L?AQ^S'\.[>\N+?3O%'C;Q]XOU*WBDECAO6\$:/X<TK3DNEC*I<Q0
M/XYFNXH;GS8A=1).%,]M"\7P9_P;]_\`)\WB?_LV[XB_^I]\,:^N_P#@Y$`6
M3]CHG<"4^.8'4*?WGP<#(>.O(;KD`$8YS7N5*2J<<8*G965&E-+W;?N\-5J;
M/2UU=K=]-3\GX<QV(P/T).+*N'JRI5*O$,\#*5YJ]#'\39#@\13]QI_O:%6=
M*S]QJ;C/W')'5?\`!-[_`()/?LL_&W]BCP=\4/C5X1U3Q1\0/BXOB;68O$&G
M^)O$&D2>$M(@U[6-$T"STBSLKNWTJ>X@@TN+5+V;4;"^)O+IK,$VL'ER?CC_
M`,$W=*ET+_@I=^S]H@D^U1Z'\8M7T*.\V+&]S%H^B^);!9WCCDDBCDN!`LSJ
MCR8D9QYA(!/];'_!)YHW_P""=_[,I2175?"&NY"X(WQ>./%*O'D$\QO&RMD9
MR,$`@@_R@?\`!/HAO^"I/P<!RN/C_P"-,=P<Q>+>1TZ?0]0>*Y\%C\7BJ?%L
M9XFM6IPIU?9TZE6I*-*E%UX2C3C.7[N*I\L7"-DXJ"<7RQ2[>/>#>%N&Z7T2
MLQR+(<LRO,,TS3A;^U,9@\%AL+C,UE5J\(8MXC,L7AX4GC<0J]2K-5L5[2I"
M5:LXRBIU%+^J+_@J1^SS^T7^U)^SY9_!G]G_`%7P]HTGB#QII=[\1+GQ#XAO
MM`AU'P9I-KJ%S%HD<^GV-_-/!J7B`:7)JED8X[>\T^RNK.Y\V&[,,GYV_LT?
M\$,/@WX/^$7B75?VS+U+WXAW5QJDD.H>$?'-[I?A#P-H5O;^5I^H6][)9Z8F
MI:I+*)-2O3JMLVGPLR6:6\T4#SR_IW_P4/\`V]/!G["OPFB\5:AI]MXJ^(OB
MZ_N-#^&_@,ZC'93:WJ$$*2ZCKFH.D<ES;>&_#:W=@^K7*1F26XU#3-,M&^W:
ME9JWX)_`WX-?\%(/^"M]A=>-?C+\>]?^&O[-NHWKV[BUL)?#_AWQ3#!.UGJ^
MD^#?`GA]].7Q3I]D_P!IL6UGQGJEWI\=_"ZQW6M>5+'7EY5+-:661E'%4\FR
MQ8CF>81<EBL5)6YZ5.-&7M:RA'W>644G;DBY<LXK]D\4<-X;XKQ1C2EPAFWB
M[XF5<AAA*7!<ZN$K\,</Y=5I8>6'QV:SS&DLMRGVCK.M&I.>(K4O;+$SH47B
M,-5G\:?\$W9)OA+_`,%2/A-X:\+Z\FL:=IGQ<^(?PO.N:=,CV7BSPM)8^+_#
MJWK2VV8+NRU2*#3];MV#26Y>UTZ6%B(;=A_>$I!S@$=,D]SDCGWP`WN&!]S_
M``8_L->#[+X>?\%5OA3\/],NKB]T[P)^TEXP\&:?>W:1Q75[9>%KOQ3H=I=W
M$4*1PQ37,%C'-)'%&D:.Y5%"@"O[SD_B^H_]`2EQDU+'X":?-SY93DY\O(ZE
MZLVIRC9-.2=^5ZQOR]#E^A>ZRX%XUPU6F\/#!^(.9TJ6!5:5>C@%_9F4NIA<
M/.4FG3IU)27/%_O&G4;<IMCZ***^1/[%$W#&<\#ZU\W_`+5G[2WP]_9,^"_B
MSXT_$J_:WT/0+1;;2]-@\UM0\3^*-0$T7A_POI441W?;M9O5$)N9=MGIMFMU
MJFHR0Z?8W,T?T:<*K#/<9)`P-Q`S@D<#.3SQU&>!7X5?M#^$KW]MW_@J/\._
MV=O%]MJ9^`?[)'P]TGXW^+]*7=#IGBWX@Z_?:=<>&[74TE9H+W3Y+:YTJTA1
M8&:2RTWQKIYE07Q:'NP%"C6KMXAOZM0C*O75U&4Z5.SY(-JRG4=H1?1R32;T
M?P?'_$.;Y'D5.GP[AZ>)XFSW'83(.'HUH2GA<-FF82<7F.-2G!RP.486&)S3
M$P3?M:>#E0O%U%./JW_!.+]D_P"(<?B'QE^W+^UE'+K?[47QYM4DTK2-7^Q7
MUI\&_AM+,]QH7A?PW&8#+H]]?Z--I\&HVXG>72])M;+1HUAO+CQ-<:Q^OPC`
M4D*H9\&0\98@8R3W]!Z#C@<4D4:QJ`HP,`!1M"A5`50```!@#A0!SR,UF:WK
MNE>'M.OM7US4],T72-.A-Q?:IK%_;:7IUG`H+22W5]>R0VEO$JX)EFE1`<@]
M,USXFO5Q52<ZBB[I0ITHK]U3I125.C3C[S]G%:*+O?5ZMN_K<*\,9;PEDF%R
MC`SKU8T?:XG&YCC:L:N89EF&*G*OC\US'$\M/V^.QM:<ZM>M*,>6+C2@J=&G
M"$>`^-6/^%9>*%X!%K9%"!PQ&JV+#:2>2!\PZ#(..<"OSFT#QEH?A'Q?X"GU
MR\F:ZU+Q/I%IH^BZ?:W.K>(?$5_:R?:Y[/0-$L([C4M8GM[:"6YNFLH98;"T
MAGO;Z>ULK:>XBI^.OVZKG]INZUGX3?L9>%[?Q[HEKJ":=\1_VC?&5OJF@_!/
MP!IMM=127=YX?N);47/Q,\20?9YFL?#NE2V%I=3QQ^=?FTE\VH?@]X`\$?"S
MQ]9^+3KNN^/?%^I:QHO_``D'Q9\:HDGB!M(2]@>]T;P9HMM"ME\//!DCJ'?0
M-%MHKW4@P_X2"YU!EE9_\\/I5\(<.X7QF\/.-./.*,%P]D^6Y7PY@<#D>$E3
MQ/%>=9E@^)<PS"\<%.#PF39-0CC*$\PSS-ZN&IT\/S+`X7'XA.DOT+@3C&IQ
M!D>:X+@K#1SFC#'8B.*XDJTYKAO"TJF'IT*U/`XJ+IU<]Q]Z52%*CE;JX2A7
MBXXW&T'#E?ZF^%-0\2:Y;3ZCKVAKX;C>8C2]&FNH+[5(;54C"W.LW5K/+8PW
MTKK*!I^G27]K9J/^0O?M,5M>S52N.>,?0_IP?Y#M7)^&?%WAOQ(+L:!JUGJ;
M6D=O-="U9R8EN#*D;2*X!3S6AE"9R3Y;`X"@#KZ_OG`8_+LXPE#,LKQF#Q^!
MKN<L-C,!7HXK"UHT:LZ,U2Q%)U*<^2I2G2J<DWRU85(W4HNWANA5P[=*NJD:
M\;>T56/+4NTI)RCR4]XM.,N2/-!J25GJ4445Z`'Y^?\`!5'_`)1[_M4=?^2;
MR=.#_P`AK1NGO7\I7_!+O]H#]IC]FSQ1\;OB5\"/@2OQ^\):;X5\._\`"X_#
M-C<W%GX@TO2$UG6;CP_K.AMIT6IZL[07`UF*^2Q\+^(4^RF)[J*TA@68_P!6
MO_!5'_E'Q^U1_P!DXD_]/6C5^('_``;G1++\2OVJ`XRH\'_#C(.-K`^(/%X*
ML"<,I'\+`J2`2,J"/M,DJTZ/#F=5:V'I8JE'$87GH5G-4ZD95*,;.4)0E%IR
M4H24M)QBVFKI_P`5>,F6X[./I-^#N79;G6.X>QU?A;.I87.,MIX6KC,%6HTN
M(J\90I8W#XK#5:554GA\51JT9*KA:U:$94YRA4A^6WQZ^+7QJ_X*L?M@66I>
M#OAO]D\>^)=+T'P%X8\">'[^Y\11^$O"?AZ[NE>_\1ZU)I]J8=.M-3UW6]6U
M_6[W3M+TW3(;WR%A^T!I9_[JO!WPFT'PE\&?"GP6L4ED\.^#_`'AWX>V$K>4
MLZV'AO0[#1K.Z!W,OVM18Q7!D()-QN<#:5+=MH_@?PCH-U<:AHWAS1-,U"]Q
M]MO['2K&UO;SD,3<W4,"SSLS99FDD9BS%B<\UU*J%S@G&``"<@!1@`>G'7U/
M/7-?-<48G!<496LCQ>74%D[P6,R^O@I6K0Q.%Q]%8?$4:TIQNZ<J'/34=^6K
M4<I2<DX_M/A!X18KPTS;BWBC-.*<5Q3Q9QAF&'QV8YO4P='`0I+"UL1B*,*&
M'A.NXSG6Q,I5G[54.6EAX4,/15-\_P":MUI/C?X.^*%U#RY+.ZM7NXK+4XU\
MS2]3LY603)*\82/9<^7&9K1Y([JWEC4KN7RV:;Q1X_\`&_Q9?3-+>SAO&MKE
M9+?3M"LKORI+J=7A^USB2ZNY&,$9>)9&6*./S7[,S#]%KBSMKH.EQ!%-&6;*
M2I&ZL<Y!*NI!Y`(.-W'!J*WTK3K5O]&M8("<$^3$D);G')0+N&.BDD<@[<X(
M_P`]JWT,<WPL,TX7X=\8>),H\,,[QD<9F'",J<Z\Y)58U/8JI3Q5'+IM2A2C
M[6I@XNNJ5%XNE6E2C)?U<^-</6E3QF+R>C6S2C%1HXJ$HQA!>ZFY1UJI/WO=
MC/3F:3U=_*_@GX&U#P/X4E@UB**#5M6OY=2NH(7$BVJ"&.WM+=I%;89E@1I+
MD+YB"YN)5C<QHE?-_P"TL"?B);.%8HOAG3LE5+8V7FM,P.`3G:RD#&6!^7/-
M?>?'````XQT&.F>HZ>G7W/`J%[6"9B\D2,0=GS(C''!&6920`20!T'3KT_9^
M._H]Y/Q3X-9)X.9#F];(\JR&OE57!8_%4(X[$UUECQ<JU3$PA]4B\3CL3C:N
M)Q%2$(0]M.;A",&DO"P'$-?"YW6SJO0CB*M=5E*E";IJ/MG322YW.2C",%&*
MO)I63[G)?#P?\4'X,C8$.GA30`RNI5E*Z99ALA@.F<$_A7\UG_!Q)\"3=77P
M#^/NAZ-<37]W!K_P@\7W=I:2W+7%I:B3QAX%\]+='V+:33^.K<S7"B-VU"UM
M_-5A%')_4/'$L:`(,`(%"\``8``PH4<``#V&!BJ=W965\`MY;6]V(V698YHH
MI0DD8*AP'5BI&6&X?,%9E#!6(K^BN"?:<)8;),-&4<7/)\JP6`G+E=.&*A@\
M!0P4ZG*VW"-3E]HJ;E*4'*#O=7/QWQ8X%P7BCP?GO"F-Q+R]9Q5H8BACHTHU
MYX'&8;'T<PH5Z=.4X<]JE%TIPYXN=&I4I\WOL_F*_P"#=SX%M"_[07[0.MZ+
M<6VH?\4U\*O!]]>6;VMPEG*I\5^-FM'N%0RVU[-'X*B:6W/D,^FSQAY'#*G[
MR?ML)(W[&_[5J!)))'_9T^-,<<<:/-+)(_P[\0I%%%%&'DFFE=@D442-++(R
MQHC.RJ?I6QL+2PB:.SMH+:.1O,:.WABA0L0!N*Q*BDE0!G&<`#H!B>XBBGAE
MAG1)8)4*31R*KQR1MPZ.C@JR.I*L&&"I->YF&93S',GF%2FH-SI.-*#?+"-*
M-."C%N]KJFFW;63;:=SSN`/#7`^'_AQA^`,#C7B(4<%FM&OFLZ"A/$XG-:V*
MKUL74H1J*_LWB(TX4W5NJ%&G24XI*W\8_P#P0#T_4+/]N+Q+/=Z=J-K`_P"S
MG\0(%GN-/O(8C-/XZ^&LT,7F20J@DEBBEEC0L&>.*1U!5'(_5?\`X+R_LU_$
M/XU_L_?#?XD?#KPO>^+-1^!WBKQ#JOBG3M+C%SK%MX#\3:3:0:QK&G:?%YEY
MJS:?J6@Z`]Y86$<ETNGRW-^MM*EA(8_W0MM&TNSD\^VLK.WD*%3)#:V\+,K!
M`58Q(AQ^[1L?=W`-C(%76@C>-HY2LBL-I#!"""<D$%<$>QSGD=Z[JN?UJN<4
M,XC1A"K0=*]*\G":IKDM?25I1DU+6^J:LM#XSAWP%RC)O"+-O"+&YUBLQR[-
MJV.KSS:&&H8:OAJV*Q.%QF'J0H3G6A.6&Q&$HU(75I6E&2U3C_&=_P`$\O\`
M@J1^TS\,?A/I/['WP;_9[M_V@O&VFZGXA?X;75KKVKVUWX4TO7M2O-3U"S\5
M:%8:/?+<:)H>OZG>7S:E>:[X6L].T^=['4K^SM[:&2OF?_@GUX8\:^%_^"GW
MP4TCQQIL\7B31/CQXQTOQ1>VUI=#1Y==TZ+Q99:Q=:?.]M`ITV?5(Y7LY]D4
M4L$UJ$2,21*W]U&E^#/"6@W%W=Z+X=T32+J]<SWMWIFF6-C<7,I8L6GDMH8F
ME)/)WELL2S?,23I#1M*2=)H--L(Y=S3F9+.V\WS=Q8OO\HN)&9RQ8$$MU)Y!
MZJO$F&MF'U;*Z6%>84JD<14]O*51SJ1DI2;LH67.Y<D()2EK)R]VWQV&^C;G
M%>/AXN(_$[-,^I^&^=Y=C<AP<LFP>&P%'*\OQ.#KX?`1A"H\34K5?J=##5,;
MBL76A##T:4*.'I6FZG\V_P#P<*_`KXH^--/^!7QF\)>&=6\1^!OAUI7C_P`.
M>.;K2H9+R;PN?$U_X5O]+U6\LH8Y+F+1[R+0]0MK_4EB-O9S0VZ7\L$=Q;%O
MD']BW_@K)^TMH/P*\$?L>_`']G#3/BU\2_#NG:AX3\"^+M&U+5+N+3[34+RZ
MGTO5_%'A33])-@6T&?4$6_U+4?%^AZ3<I;G4=7O+%)KEX_[#+BQM;R*XMKZ*
M.YMKE72:WN8DD@DCD#!XWCD0AT;(W(<JVWD$%A6-H_@GPAX=2;_A'_#>AZ*;
MG>9FTO3+*PDD,GWV,EK%"V]N<L#NSR#NYKFPF>X>GE]'+\5E]''4L-5=;#N5
M6I32G-N3=51?[Q7DXI)TUR_$I-IKZ3B#P,SS%>)6=>(G"GB)F?!V(XGRW#9=
MQ#@\)EF`S#$UJ.'HX/"I9?B<5STL&Y4<OPM2,YX;$UH5Y5ITJL(5%2C_``M?
ML-Z-\0_#O_!4/X01?%JTU"W^(-A^T1XB@^(EQ>PV[N_C:2Y\1P^)+B6?2HET
MJ=;OQ!)=R1W>EC^RKH3)<:>S64L+'^\V,@[@#R"N1W'R+P1V/L:S(]&TI9?M
M']G6*W1E,WV@6L`G$Q8DR^:5\PR%LG?G=GGKFM..,)DY))"@Y/`"YP,#C//)
MZGC).*Y<ZS7^V,31Q'L%A_8X=8?D4N:+2DYWCI'E2<N6,=;125WN?6>#/A/2
M\(<FSS)J&>8OB"&=<08C/7C,=AX4,72]OA,)AO8XB4*M18BN_JL:M6NHTE4G
M4F_9QT2DHHHKQS]B.>\27&J)X;UZ;0X%N-:BT;4I='MY615FU..TE:PA<N-@
M66[6)26RNTDMQFOPB^$7_!97]CK2]*TS6?CGX;\9_#7]HCP[X/TOP!\2HIO`
MHO=0FU#P^=NJ:9;:K9W*W4^G1^(%O[JTLM2CAF@:YV@,)/.;]^V16!4YP003
MG!P3GK[8X]*\5UC]FSX!>(?$I\8ZY\'_`(>ZMXI:9+EM?O\`POI5QJ;W"/YB
MSO=26QD>429D+L2Q<EB2>:[<+6PE.,X8K#U:BERN,Z%94:L>56<.:4*D'">\
MKP<KI6:U3^`XRR;CG'ULMQ?!6?Y#E-;#.O3QN%XDR6OG>7XBG5G2J4L10A@\
M=EN+P^/PDH5(4:D,6J-2E7J1K4I-4Y0_*N7_`(*G?%#X^FX\+?L,_LG_`!/\
M?:[J"H^G_$7XI:<W@OX:Z1:WC"VBUBZFGN-FJ06GFI=_8+#57GFB3S(K251(
MBL\'?\$W/C]^T;XLB^)?_!17X\7WC^W@;3[G1O@-\,]2U#P]\+](DMI':>'4
M_L@T]M:M9MD<4UK'8V/VL?:DU.?5()]J_MA8Z)I&F0I;Z;IMEI\$>`D-C;0V
MD2@;,*J0)&H&44D8_G6@(D&.IP-HR>@SGMCOS6\LQIT5-9=A:>$<DXNM-_6,
M4XV2:]O-)4[J]W1ITWJTVT[+R*?AK7SJIA\1XB\2YEQE/#5(UJ.3THPR'A*E
M63YN:ID6`G[3-8QG9PCG^89K2IRITYTJ,*J=0X+1_AKX#\/Z%IWAC1_"/A_3
M?#VDP16VEZ-8:79VVGV-O%&L<<,-K%$L")&J*%VH#@G<6)R+H\"^#AT\,:%_
MX++7/X_(*[+8OIGZ]^W/M[=*4*H[#\J^,Q_"W#F;8F6,S;(,CS+%SA&$\3CL
MHP&,Q,E#2,77Q%"I4<8IM)-_<?KE#$XC"T*>&PM:MA\/22C3H4:U2C1IP5O=
MA2I.,(I6LDDM'8P])\/:+HS3OI&E6&FM.J+,UC:Q6QE";_+\SRE'F&,R.8]W
MW=[XQN-;@&`!UP`,_2EP!T`%%>I@<!@<LPM+`Y=@\+@,%0Y_8X3!X>CA<-2]
MK4G6J>SH4(4Z5/GJU*E2?)!<]2<IRO*4FXG4JU9.I6G.I4DES3G.524N5**O
M.;<G9))7>B22T2"BBBNL@YSQ/X:T'Q?H^H>'/$^C:;X@T#5H#:ZIHVKV=M?Z
M;J%L2CF"\L[J.2&XB+(K;)%9<J#C(&.2^'_P>^%WPQNM1O/A]\//!?@BYU>W
MM[;4YO"OA[3M%EOX+666:VANWL;>$W$=O+<3R1"0L%:9F`!)KT_`]!^5+0IU
M-8W]Q[KF>MK-76V_Y(PGA<-.M#$3P]&>(I7]E7G2I2JT[IQ?LZDJ;J4[IR3Y
M)JZDTVTV@HHHH-PHHHH`****`"C`]/;\/2BB@`HHHH`****`"BBB@`HHHH`*
****`"BBB@#__V3\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
